Efficacy and safety of gilteritinib combined with chemotherapy in newly diagnosed FLT3-mutated acute myeloid leukemia
10.3760/cma.j.cn121090-20240615-00224
- VernacularTitle:吉瑞替尼一线联合化疗治疗FLT3突变阳性初诊急性髓系白血病16例的疗效及安全性分析
- Author:
Yutian LEI
1
;
Xiaoli ZHAO
1
;
Ming HONG
1
;
Wenjie LIU
1
;
Qian SUN
1
;
Sixuan QIAN
1
;
Shuai WANG
1
;
Yu ZHU
1
Author Information
1. 南京医科大学第一附属医院，江苏省人民医院血液科，南京 210029
- Publication Type:Journal Article
- From:
Chinese Journal of Hematology
2024;45(12):1129-1133
- CountryChina
- Language:Chinese
-
Abstract:
This study aimed to assess the efficacy and safety of gilteritinib combined with chemotherapy in treating newly diagnosed FLT3-mutated acute myeloid leukemia (AML). We retrospectively collected clinical data from 16 patients newly diagnosed with FLT3-mutated AML at Jiangsu Province Hospital. Patients received induction therapy with the classic "3 + 7" regimen or the VA regimen, and all patients were immediately supplied with gilteritinib after detecting FLT3-ITD/TKD mutations. Of the 16 patients, 12 were male and 4 were female, with a median age of 52.5 years (range: 15-76 years). Additionally, 15 patients had FLT3-ITD mutations and 1 had FLT3-TKD mutation. The complete remission (CR/CRi) rate was 93.8% (15/16) after the first cycle of gilteritinib-based induction therapy, with 13 patients achieving MRD negativity detected with flow cytometry. All patients achieved a CR MRD- during the consolidation phase. FLT3 mutation clearance was achieved among all 14 patients who underwent next-generation sequencing (NGS) analysis. The 12-month overall survival and relapse-free survival rates were both 73.9%, respectively, with a median followup of 18 months. Nine (56.2%) patients experienced infectious fever during the induction therapy. Three patients had grade 3 QTc prolongation during consolidation and maintenance therapy. Treatment-related adverse events were generally tolerable.
